The Regulation Of β₂ Adrenoceptor Agonist/antagonist On The Osteogenic Differentiation Of Human Bone Marrow Mesenchymal Stem Cells In Vitro

ObjectiveThe purpose of this study was to detect the expression of β₂ adrenoceptors on human bone marrow mesenchymal stem cells (hMSCs) and investigate the effect of β₂ adrenoceptor agonist/antagonist on the mRNA expressions of BMP2 and cbfa₁ during the process of osteogenic induction (OSI) of hMSCs in vitro. MethodThe hMSCs of a healthy adult volunteer bone marrow were isolated by the method of density-gradient centrifugation. The hMSCs were affirmed by flow cytometry(FCM) and OSI. At the third passage, the β₂ adrenoceptors mRNA on hMSCs was detected by Real time Quantitative PCR. Then hMSCs were divided into three groups by randomization: A (β₂ adrenoceptor agonist group), B (β₂ adrenoceptor antagonist group) and C (normal control group). During the process of hMSCs to differentiate toward osteoblasts in vitro, A and B groups were given 1 μmol/L, 5μmol/L and 10μmol/L Salbutamol (β₂ adrenoceptor agonist) and ICI-118551 (β₂-adrenoceptor antagonist) respectively. The mRNA expressions of BMP2 and cbfa₁ were measured by PCR at 48 hours, 72 hours and 96 hours respectively.